HVTN approved WHV proposal to conduct an exploratory study to better characterize the immune responses observed in volunteers in the HVTN 124 clinical study testing WHV’s PDPHV vaccine candidate.
HIV Vaccine Trials Network is conducting immunogenicity assays to assess the peak immune responses observed two weeks after the last immunization in the HVTN 124 trial. At the same time, WHV plans to supplement HVTN’s work by conducting its own investigation into the dynamics of immune responses, as well as conducting additional assay to better assess the breadth and potency of antibodies elicited by the PDPHV vaccine candidate. WHV formally applied to HVTN to request the samples from volunteers needed for the study and the request has been approved.
This work will be conducted in collaboration with Dr. Shan Lu’s Laboratory of Nucleic Acid Vaccines (LNAV) at the UMMS in Worcester, MA. Dr. Lu is the co-inventor of the PDPHV vaccine candidate and his laboratory has extensive expertise in assessing immune responses to the DNA/protein vaccines. Another co-inventor, Dr. Shixia Wang, will lead the studies. The results from both the HVTN study and the exploratory study by WHV will be available later this year.
